A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma

Metaplastic breast carcinoma (MBC) is a rare malignant breast tumor, and no effective chemotherapy unique to metaplastic carcinoma exists. As MBC is typically “triple negative”, endocrine therapy and molecular therapy targeted to Her2 might not be favorable, resulting in a poor prognosis. Anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Jieya, Yang, Xiaojuan, Duan, Jiajun, Wang, Ji, Yang, Zhuangqing, Luo, Dan, Liu, Lihua, Chen, Junyao, Nie, Jianyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408045/
https://www.ncbi.nlm.nih.gov/pubmed/34475766
http://dx.doi.org/10.2147/OTT.S318645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408045/
https://www.ncbi.nlm.nih.gov/pubmed/34475766
http://dx.doi.org/10.2147/OTT.S318645

Ejemplares similares